Navigation Links
FDA Cleared New Application for Simbionix PROcedure Rehearsal Studio
Date:2/23/2012

CLEVELAND, February 23, 2012 /PRNewswire/ --

Simbionix USA Corporation, the world's leading provider of medical education and simulation training, is pleased to announce that Simbionix received FDA clearance for the EVAR (Endovascular Aneurysm Repair) application for the PROcedure Rehearsal Studio™ (PRS). Last year Simbionix received clearance for the PRS Carotid Intervention application.

     (Logo: http://www.newscom.com/cgi-bin/prnh/20120214/511292)

 

The PROcedure Rehearsal Studio transforms the patient's CT scan into a 3D visualization model. Simbionix has developed a revolutionary technology to use this 3D visualization model within its endovascular simulator, the ANGIO Mentor, to allow surgeons to evaluate endovascular surgical treatment options before surgery. PRS provides a 3D model of the patient's vasculature and true-to-life vessel measurement tools.

After exporting the 3D model into the ANGIO Mentor simulator practice environment, the physician is able to train and practice aneurysm repair on the patient's specific anatomy. For the first time, surgeons can practice endovascular abdominal aortic aneurysm repair, including precise deployment of the bifurcated and contralateral leg stent graft, deployment of iliac and aortic extensions and touch-up ballooning.

According to Dr. Yael Friedman, Director of Regulatory Affairs for Simbionix, the Simbionix track record in advanced medical education and training is unmatched, with more than 140 studies documenting the effectiveness and value of Simbionix medical simulators. "Based on this foundation, and on quality control, development, and production processes that were put in place over the past few years, we are pleased to be able to move beyond training and also provide the market with a clinical tool," Dr. Friedman said. "We are very proud that the FDA has cleared the EVAR application and continues to recognize the clinical component of the PROcedure Rehearsal Studio."

About Simbionix USA Corporation

Simbionix is the world's leading provider of simulation, training and education products for medical professionals and the healthcare industry. The company is committed to delivering high quality products, advancing clinical performance and optimizing procedural outcomes.


Visit: http://www.simbionix.com  
Contact: Rebecca Levy, Manager of Marketing Communications, at rebecca@simbionix.com

+1-216-229-2040 Ext 128


'/>"/>
SOURCE Simbionix USA Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Abbotts Genetic Test for Acute Myeloid Leukemia Prognosis Cleared by FDA
2. Mesoblast Cleared to Begin First Phase 2 Clinical Trial for Eye Diseases
3. NeuroQuant®, CorTechs Labs FDA-Cleared System for Quantifying Regional Brain Atrophy from MRIs, Used to Identify Patients at Highest Risk for Developing Dementia
4. Masimo rainbow Acoustic Monitoring Technology Cleared for Market in Japan
5. New FDA-Cleared Sensititre® AIM™ Automated Inoculation Delivery System Provides Faster, Accurate Dosing of MIC Plates for Microbiology Laboratories
6. Rapid Fire Marketing: Medical Cannabis Management Cleared for Medical Cannabis Cultivation
7. Breakthrough CardioHealth® Station Cleared By FDA to Take Center Stage at the Annual Scientific Sessions of the American College of Cardiology 2011
8. Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System
9. Mobile MIM, First FDA-Cleared Diagnostic Medical Imaging App, Now Available on the U.S. App Store
10. Luminex Corporation Launches New FDA Cleared Pharmacogenetic Diagnostic Test
11. Zargis to Launch FDA-Cleared Lung Sounds Analysis Technology from Stethographics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 23, 2016 Research and Markets ... Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic ... Coating, Parenteral) - Global Forecast to 2021" report ... The global pharmaceutical excipients market is projected to ... of 6.1% in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):